6YVA image
Deposition Date 2020-04-28
Release Date 2020-05-13
Last Version Date 2024-01-24
Entry Detail
PDB ID:
6YVA
Keywords:
Title:
PLpro-C111S with mISG15
Biological Source:
Host Organism:
Method Details:
Experimental Method:
Resolution:
3.18 Å
R-Value Free:
0.29
R-Value Work:
0.24
R-Value Observed:
0.25
Space Group:
P 62 2 2
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Replicase polyprotein 1a
Chain IDs:A
Chain Length:315
Number of Molecules:1
Biological Source:Severe acute respiratory syndrome coronavirus 2
Polymer Type:polypeptide(L)
Molecule:Ubiquitin-like protein ISG15
Gene (Uniprot):Isg15
Chain IDs:B (auth: C)
Chain Length:161
Number of Molecules:1
Biological Source:Mus musculus
Ligand Molecules
Primary Citation

Abstact

The papain-like protease PLpro is an essential coronavirus enzyme that is required for processing viral polyproteins to generate a functional replicase complex and enable viral spread1,2. PLpro is also implicated in cleaving proteinaceous post-translational modifications on host proteins as an evasion mechanism against host antiviral immune responses3-5. Here we perform biochemical, structural and functional characterization of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) PLpro (SCoV2-PLpro) and outline differences with SARS-CoV PLpro (SCoV-PLpro) in regulation of host interferon and NF-κB pathways. SCoV2-PLpro and SCoV-PLpro share 83% sequence identity but exhibit different host substrate preferences; SCoV2-PLpro preferentially cleaves the ubiquitin-like interferon-stimulated gene 15 protein (ISG15), whereas SCoV-PLpro predominantly targets ubiquitin chains. The crystal structure of SCoV2-PLpro in complex with ISG15 reveals distinctive interactions with the amino-terminal ubiquitin-like domain of ISG15, highlighting the high affinity and specificity of these interactions. Furthermore, upon infection, SCoV2-PLpro contributes to the cleavage of ISG15 from interferon responsive factor 3 (IRF3) and attenuates type I interferon responses. Notably, inhibition of SCoV2-PLpro with GRL-0617 impairs the virus-induced cytopathogenic effect, maintains the antiviral interferon pathway and reduces viral replication in infected cells. These results highlight a potential dual therapeutic strategy in which targeting of SCoV2-PLpro can suppress SARS-CoV-2 infection and promote antiviral immunity.

Legend

Protein

Chemical

Disease

Primary Citation of related structures